MIR519D: MIR519D is a microRNA that has been studied in various contexts, including hepatocellular carcinoma (HCC) [PMC5074303], central nervous system (CNS) tumors [PMC8235499], non-alcoholic fatty liver disease (NAFLD) [PMC9775974], and breast invasive carcinoma [PMC6193703]. In HCC, MIR519D has been shown to target TIMP2, a member of the TIMP family that regulates the activity of MMP2 [PMC5074303]. However, in hypoxic HCC cells, MIR519D up-regulation was not observed [PMC5074303]. Interestingly, MIR519D is overexpressed in the majority of CNS tumors [PMC8235499]. In NAFLD, MIR519D is elevated and directly targets PPARα mRNA [PMC9775974]. In HCC tumorigenesis, MIR519D has been validated to play a specific role [PMC6338110]. It is also associated with stem cell biology and tumorigenesis [PMC8508841]. Additionally, MIR519D expression has been found to be increased in adipogenesis-promoting cells but decreased in another subtype [PMC6307768]. Furthermore, little to no expression of MIR519D was observed at the RNA level in patients with certain pathologies [PMC9623263]. Disruption of MIR519D has also been observed along with its target genes in certain individuals from different regions [PMC3938728]. Hypomethylation of the CpG island of miR-519d and miR-429 resulted in increased expression of MIR519D in HCC [PMC8904560]. Finally, based on module genes analysis, it was predicted that MIR106A, MIR106B, MIR20B, and MIR519D may be involved in certain diseases or conditions [PMC9208509].